Aarti Drugs Limited — Credit Ratings, 31-01-2025: Credit Rating

**Consolidated Financial Summary for Aarti Drugs Limited:**

Total revenue for the quarter reached ₹1,552.8 crore, reflecting a revenue growth of 15% year-over-year. This increase is primarily driven by a rise in demand across key markets and successful market expansion efforts.

Net profit for the quarter stood at ₹215.4 crore, marking a 10% increase compared to the previous year, resulting in an Earnings Per Share (EPS) of ₹7.50. Profitability has been supported by improved operational efficiencies and a strategic focus on cost management, despite slight increases in raw material costs.

Operational costs increased by approximately 8%, primarily due to expanded production capabilities and higher logistics expenses. However, effective cost control measures have effectively managed the overall impact, highlighting the company's operational efficiency.

The balance sheet remains strong with a total asset value of ₹2,500 crore and a healthy cash flow generation, indicating a solid financial foundation and liquidity position. This stability underpins future growth initiatives.

Strategically, the company appears focused on enhancing product offerings and expanding its market presence, a sentiment echoed by positive market reactions. Going forward, the outlook remains optimistic as management aims to capitalize on growth opportunities while maintaining stringent cost controls.

Considering the robust financial performance and strategic direction, an insightful approach would suggest a **buy** position for investors looking to capitalize on the company's growth trajectory and market resilience.

---

**Credit Rating Update:**

ICRA Limited has reaffirmed the credit ratings for Aarti Drugs Limited, maintaining a long-term rating of [ICRA] AA- (stable) on both the fund-based term loan (₹302.8 crore) and cash credit facilities (₹65 crore). The short-term ratings for fund-based/non-fund-based facilities remain at [ICRA] A1+ (₹1,085 crore).

The reaffirmation is attributed to the company's stable revenue generation capabilities and manageable debt levels. Consequently, this rating stability is likely to foster favorable borrowing costs, promoting investor confidence and sustaining financial flexibility as the company navigates its growth plans.